Apeloa Pharmaceutical Co.,Ltd
000739
Kedudukan dalam Saham
#4290
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Harga Saham
$3.13
Modal Pasaran
$3.62B
Perubahan (1 hari)
-1.42%
Perubahan (1 tahun)
46.59%
Negara
CN
Perdagangan Apeloa Pharmaceutical Co.,Ltd (000739)
Kategori
Healthcare
Hasil untuk Apeloa Pharmaceutical Co.,Ltd (000739)
Hasil pada Jun 2026 TTM: $1.33B
Menurut laporan kewangan terkini daripada Apeloa Pharmaceutical Co.,Ltd, hasil semasa syarikat (TTM) ialah $1.33B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $1.65B peningkatan berbanding hasil pada tahun 2023 iaitu $1.62B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Apeloa Pharmaceutical Co.,Ltd dari 2000 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $1.33B | -4.81% |
| 2025 | $1.39B | -15.31% |
| 2024 | $1.65B | 1.61% |
| 2023 | $1.62B | 6.03% |
| 2022 | $1.53B | 8.65% |
| 2021 | $1.41B | 16.65% |
| 2020 | $1.21B | 16.48% |
| 2019 | $1.04B | 11.72% |
| 2018 | $926.93M | 8.63% |
| 2017 | $853.30M | 24.14% |
| 2016 | $687.35M | 2.89% |
| 2015 | $668.02M | -2.25% |
| 2014 | $683.37M | 7.52% |
| 2013 | $635.58M | 13.89% |
| 2012 | $558.08M | 25.04% |
| 2011 | $446.31M | 93.68% |
| 2010 | $230.44M | 15.01% |
| 2009 | $200.35M | 11.32% |
| 2008 | $179.98M | 26.18% |
| 2007 | $142.64M | -5.97% |
| 2006 | $151.70M | 18.26% |
| 2005 | $128.27M | 27.82% |
| 2004 | $100.36M | 7.83% |
| 2003 | $93.07M | 16.84% |
| 2002 | $79.66M | 364.75% |
| 2001 | $17.14M | -20.73% |
| 2000 | $21.62M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 397.95% |
IN
|
